Do you have to stay on a GLP-1 medication forever? 5 things to know

glp-1 metabolic health weight loss Oct 23, 2026

For some people, staying on a GLP-1 medication long term is the right call. For others, it isn't. Here's what the research says happens when people stop, and five things that help, whichever way you go.

By Dr Lucy Burns and Dr Mary Barson, medical doctors and co-founders of Real Life Medicine. October 2026.

You're at the GP for your script renewal. Eight months in, the scales have moved, your knees are thanking you, and the biscuits in the pantry have finally stopped calling your name at 3 pm. Then the question you've been carrying around for weeks pops out: "So, do I have to be on this forever?"

It's one of the most common questions we hear. Sometimes it's about cost. Sometimes it's side effects, or a supply hiccup at the pharmacy. And sometimes it's a nagging worry that needing a medication means you've failed. (It doesn't.)

A few weeks ago we wrote about the black market in peptides: the unregulated online sellers, the untested vials, and the risks of buying hormone-like products without a doctor. This week is for everyone else. The many women taking a GLP-1 medication, such as semaglutide or tirzepatide, prescribed by their doctor, who want to know what happens next. And if you're still deciding whether to start one, this is a question worth asking before you begin, not after.

The honest answer to the forever question? For some people, yes, and that's a perfectly good medical decision. For others, no. And what you do while you're on the medication can shape what happens if you stop.

The short answer: not necessarily. For some people, long term is the right call, and for others it isn't. Either way, five things help.

Know that long term can be the right answer, and it isn't a failure
Plan any stop with your doctor, because stopping doesn't have to mean starting from scratch
Keep lifting, the habit that held up after treatment stopped
Build your eating habits now, while the food noise is quieter
Don't do it alone, because support makes it easier to keep going

Why this matters

GLP-1 medications are now part of everyday life in Australia. An analysis of more than 16,500 Australian adults prescribed semaglutide through an online weight loss service found that only around half were still taking it six months later. Higher program cost and pausing treatment were among the strongest predictors of stopping.

So stopping is common, and it often isn't because someone decided they were "done". Cost, side effects, supply, life getting in the way: it all happens. That makes it worth planning for, whether stopping is on your mind or not.

What happens when people stop?

In the STEP 1 trial extension, adults who'd lost an average of 17% of their body weight on semaglutide over 68 weeks were followed for a year after stopping. When the medication (and the trial's lifestyle program) stopped, they regained about two-thirds of the weight they'd lost, and improvements in things like blood pressure and blood sugar mostly drifted back towards where they started. In the SURMOUNT-4 trial, people who switched from tirzepatide to placebo regained 14% of their body weight over a year.

A large 2026 review in the BMJ pulled together 37 studies and more than 9,000 people who'd stopped a weight management medication. On average, weight came back at about 0.4 kg a month, and markers like blood pressure, blood sugar, and cholesterol were projected to return to where they started within about a year and a half. Weight also came back faster after stopping a medication than after finishing a behavioural weight program (one that teaches eating, activity, and mindset skills).

Why does this happen? GLP-1 medications work by turning down the appetite signals between your gut and your brain. When the medication stops, those signals usually come back. On top of that, after weight loss the body adapts in ways that push hunger up and energy use down. That's biology, not a lack of willpower.

But averages hide a lot of individual stories. Here are five things that make a difference.

Before you start: these tips work alongside your medication and your medical care, not instead of them. Please don't change your dose, or stop your medication, without talking to the doctor who prescribed it.

Five things to know about staying on (or coming off) a GLP-1 medication

1. For some people, long term is the right answer

The STEP 1 researchers summed up their own results this way: obesity behaves like a chronic condition, and ongoing treatment seems to be needed to keep the improvements in weight and health. That's not a judgement on anyone. We don't think twice about someone staying on blood pressure tablets because their blood pressure goes back up when they stop.

The flip side is in SURMOUNT-4. People who kept taking tirzepatide for another year lost a further 5.5% of their body weight, while those switched to placebo regained 14%.

Long term doesn't always mean "top dose forever", either. In one Danish general practice, of the people still taking semaglutide a year after starting, 40% were on 1.0 mg a week or less (below the 2.4 mg dose used in the big trials), and on average they'd lost 13.6% of their body weight. That's one practice and an observational study, so it can't tell us what's right for you. But it's a good example of why the dose and the duration are a conversation, not a set rule.

Some questions worth taking to your GP:

What am I taking this for: weight, blood sugar, my heart, my liver, or a mix?
What would tell us it's time to review the dose or the plan?
What's our plan if cost or supply becomes a problem?
If I stop one day, how will we keep an eye on things afterwards?

If you're on a GLP-1 medication for type 2 diabetes or another health condition, the conversation about stopping is different again. Talk it through with your doctor before changing anything.

2. Stopping doesn't have to mean starting from scratch

The trial averages above sound bleak, but they're averages. Real people vary a lot.

In a follow-up of the SURMOUNT-CN trial in China, adults who'd taken tirzepatide for a year regained about 9% to 12% of their body weight in the six months after stopping. But they were still about 9% to 11% lighter than when they started, and some of their improvements in heart and metabolic health were still there.

In a US health system study of almost 8,000 adults (average age 56, nearly two-thirds women) who stopped semaglutide or tirzepatide within a year of starting, average weight a year later was about the same as when they stopped. There was a big range between individuals, though. About one in five restarted the same medication, about a third started another treatment such as a different medication or lifestyle support, and on average they'd lost less weight in the first place (about 8%) than people in the big trials. So it's a mixed picture, not a promise.

What this tells us is that stopping is a transition worth planning, not a cliff. There isn't a proven way to taper these medications yet, so the plan is something to work out with your doctor. It might include:

Choosing your timing, rather than stopping in the middle of a stressful patch
Agreeing on regular check-ins for the first few months
Keeping an eye on your weight, waist, and how hungry you feel, so you notice changes early
Deciding ahead of time what you'll do if weight starts creeping up, such as booking back in with your GP sooner rather than later

3. Keep lifting: the habit that held

If there's one study we'd love every GLP-1 user to know about, it's this one.

In a Danish trial, adults with obesity (average age in their early 40s) first lost weight on a strict eight-week diet. They were then given a GLP-1 medication (liraglutide), a supervised exercise program, both, or placebo, for a year. Then all treatment stopped, and researchers checked in again a year later.

People who'd been on the medication alone regained about 6 kg more in that year than those who'd done the exercise program. The exercise group had largely held onto their weight and their improved body composition. And people who'd done both were more likely to have kept off at least 10% of their starting weight.

This trial used liraglutide, an older, daily GLP-1 medication, in people younger than most of our readers, so it's not a perfect match. But it's one of the few trials to follow people after the medication stopped, and the message is hopeful: the habit you build can outlast the prescription.

Strength training also protects you while you're on the medication. Any weight loss means losing some lean mass (muscle, but also water, organs, and bone) along with fat. In a substudy of the SURMOUNT-1 trial, about a quarter of the weight people lost on tirzepatide was lean mass, the same proportion as people who lost weight on placebo. In a US trial of 160 adults aged 65 and over who all lost about 9% of their body weight, those who only did aerobic exercise lost about 5% of their lean mass, while those who did resistance training (alone or with aerobic exercise) lost only 2% to 3%. They also lost less bone at the hip.

That's the muscle that gets you up off the floor after playing with the grandkids, carries the shopping, and keeps you steady on your feet. In the Danish trial, bone density at the hip and spine also dropped more on the medication alone than with exercise alone. Bones and muscle tend to travel together, which is why we covered bones in last week's Friday 5.

You don't need a gym to start. Two or three sessions a week of:

Sit-to-stands from a chair, slowly, then without using your hands
Wall push-ups, building to push-ups on the kitchen bench
Step-ups onto the bottom stair
Carrying the shopping bags, one in each hand
Resistance bands or a couple of dumbbells for rows and presses

Our five exercises to prevent muscle loss and improve balance has more ideas. If you have osteoporosis, joint problems, or haven't exercised in a while, an exercise physiologist or physiotherapist can build a program that's safe for you and progress it as you get stronger.

4. Use the time on the medication to build your eating habits

GLP-1 medications turn down hunger, and they do it well. In one trial, adults on semaglutide ate 35% less than those on placebo when offered a lunch they could eat as much of as they liked, and reported less hunger and fewer cravings. That quieter "food noise" can feel like a huge relief.

It's also an opportunity. With the cravings turned down, it's easier to practise the eating habits you'll want to keep if the noise ever turns back up.

Put protein first. A review of 20 randomised trials in adults over 50 who were losing weight found that people eating more protein kept more of their lean mass and lost more fat. An international expert group recommends that older adults aim for around 1.0 to 1.2 g of protein per kilo of body weight per day. For a 75 kg woman, that's roughly 75 to 90 g a day, which takes a bit of planning when your appetite is small. Our high protein breakfasts are a good place to start. If you have kidney disease, check with your doctor before increasing your protein.

Eat enough. After a lifetime of being told to eat less, this one surprises people. A joint advisory from four major US nutrition and obesity organisations lists nutrient deficiencies from eating too little, and muscle and bone loss, among the main challenges with GLP-1 treatment. Regular meals built around protein, vegetables, and healthy fats make every mouthful count.

Practise the hard moments. The medication can turn down the food noise. It can't teach you what to do when stress, boredom, or a hard day show up, and they will. This is a great time to notice your patterns and try new responses while the urge is weaker. Our post on thought traps that sabotage progress is a good start.

A few ways to make it stick:

Eat the protein on your plate first, before you get full
Aim for a palm-sized serve of protein at each meal
Keep easy options on hand: eggs, Greek yoghurt, cottage cheese, tinned salmon, leftover roast chicken
Notice which foods your body feels good on now that the food noise is quieter
Keep your fluids up, and tell your doctor if side effects are making it hard to eat or drink

5. Don't do it alone

Remember that BMJ review? Weight came back faster after stopping a medication than after finishing a behavioural program. The study can't tell us exactly why. But one likely reason is that behavioural programs teach skills people keep using once the program ends, while a medication's effect ends when you stop taking it. The authors' own conclusion was to be cautious about short-term use of these medications without a more complete approach to weight management.

There are early hints that support helps after stopping, too. A 2026 analysis that pooled studies of people coming off semaglutide or tirzepatide found that behavioural or lifestyle support was linked with slower regain, although the estimate was imprecise.

And in the Australian study of more than 16,500 people we mentioned earlier, people who engaged regularly with their program's support over the weeks were much more likely to still be on their medication at six months. That's an association rather than proof of cause, and the study was run by an online provider looking at its own service. But it fits with what we see: support makes it easier to keep going.

The joint advisory we mentioned in point 4 points out that many guidelines recommend combining the medication with nutrition and behaviour support, but that this doesn't happen nearly as often as it could. It suggests options like group programs, dietitian support, telehealth, and digital programs.

Support can look like:

A GP who checks in on your strength and your plan, not only your weight
A dietitian or exercise physiologist, if you can access one
A program or community that helps with the mindset side: emotional eating, all-or-nothing thinking, and what to do on a hard day
A friend or partner who'll walk, lift, or cook with you

The medication can quieten the food noise. The skills you build around it are what you keep.

The bottom line

Do you have to stay on a GLP-1 medication forever? Some people will, and that's a sound medical decision, not a failure. Others won't, and stopping doesn't have to mean starting from scratch.

Either way, the things that protect you are the same. Make a plan with your doctor. Keep up your strength training. Use the quieter food noise to build protein-first, eat-enough habits and the skills for hard days. And get some support around you.

Pick one to start this week. Maybe it's 10 sit-to-stands while the kettle boils. Maybe it's writing down your questions for your next GP appointment. Small steps add up.

Eating real food with enough protein, building strength, and developing the mindset skills that make change stick are the foundations of My Metabolic Action Plan. Whether you're on a GLP-1 medication, coming off one, or have never taken one, My MAP gives you the Strategies, Skills, and Tools to build habits that last.

Find out more about My Metabolic Action Plan

Frequently asked questions

Do you have to stay on a GLP-1 medication forever?

Not necessarily. For some people, long-term treatment is the right medical decision, much like other medications for chronic conditions. Others stop at some point. It's a decision to make with your doctor, based on why you're taking it and how you're going.

What happens when you stop a GLP-1 medication?

In trials, most people regained much of the weight they'd lost within a year of stopping, and improvements in things like blood pressure and blood sugar tended to drift back. But people vary a lot, and some keep part of their weight loss and health improvements.

How can I keep weight off after stopping a GLP-1 medication?

Plan any change with your doctor, keep up strength training, build protein-first eating habits and the mindset skills for stressful days while you're still on the medication, and have support around you. In one trial, people who had done a supervised exercise program regained much less weight in the year after treatment stopped.

Do GLP-1 medications cause muscle loss?

Any weight loss involves losing some lean mass, which includes muscle. In trials of GLP-1 medications, about a quarter of the weight lost has been lean mass, a similar proportion to other forms of weight loss. Eating enough protein and doing resistance training can help you keep more of it.

References

Talay L, Xu C, Alderete J, et al. AI patient support and 6-month medication adherence in a digital obesity program: a retrospective analysis. Diabetes Obes Metab. 2026;28(11):9980-9990. Read the study
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. Read the study
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. Read the study
West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. Read the study
Shah E, AlShiab R, Abdo A, et al. Clinical management of weight regain and cardiometabolic consequences after discontinuation of GLP-1 receptor agonists. Diabetes Obes Metab. 2026;28(6):4546-4558. Read the study
Skandov MD, Christensen KM, Dalin DA, et al. Real-world use of semaglutide for weight management: dose titration, discontinuation patterns and weight changes. Diabetes Obes Metab. 2026;28(10):8905-8912. Read the study
Chen C, Ying Z, Tang Q, et al. Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial. Life Metab. 2025;4(5):loaf024. Read the study
Gasoyan H, Schulte R, Boyer CB, et al. Obesity treatments and weight changes in clinical practice after discontinuation of semaglutide or tirzepatide. Diabetes Obes Metab. 2026;28(6):4795-4805. Read the study
Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024;69:102475. Read the study
Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. Read the study
Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376(20):1943-1955. Read the study
Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2416775. Read the study
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. Read the study
Kim JE, O'Connor LE, Sands LP, Slebodnik MB, Campbell WW. Effects of dietary protein intake on body composition changes after weight loss in older adults: a systematic review and meta-analysis. Nutr Rev. 2016;74(3):210-224. Read the study
Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-559. Read the study
Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. Read the study
Kow CS, Thiruchelvam K, Ramachandram DS, et al. Weight regain trajectories after discontinuation of semaglutide or tirzepatide: a reconstructed aggregate-data Bayesian longitudinal meta-analysis. Endocrinol Diabetes Metab. 2026;9(5):e70325. Read the study

This content is for general information only and isn't medical advice. Please talk with your doctor before making changes to your health care, including any medication.

Dr Mary Barson and Dr Lucy are the founders of Real Life Medicine. They help women who have been on every diet under the sun optimise their health and achieve weight loss without feeling miserable or deprived.

They do this with their 3-step framework that

Improves metabolism
Develops mindset skills
Provides tools to implement it easily into busy lives

With this comes increased energy, vitality and confidence.

You can avoid chronic disease and stop living life on the sidelines!

You can find out more about My Metabolic Action Plan here